Topics

Clinical Trials About "Takeda opens vaccine plant dengue shot shows promise" RSS

00:20 EST 12th December 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Takeda opens vaccine plant dengue shot shows promise" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Takeda opens vaccine plant dengue shot shows promise" on BioPortfolio

We have published hundreds of Takeda opens vaccine plant dengue shot shows promise news stories on BioPortfolio along with dozens of Takeda opens vaccine plant dengue shot shows promise Clinical Trials and PubMed Articles about Takeda opens vaccine plant dengue shot shows promise for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Takeda opens vaccine plant dengue shot shows promise Companies in our database. You can also find out about relevant Takeda opens vaccine plant dengue shot shows promise Drugs and Medications on this site too.

Showing "Takeda opens vaccine plant dengue shot shows promise" Clinical Trials 1–25 of 5,900+

Extremely Relevant

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.


Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

The purpose of this study is to evaluate the safety and immune response of a naturally aged lot of tetravalent dengue vaccine (TDV) in healthy participants, aged 18 to 60 years, in non-endemic country(ies) for dengue.

Safety and Immunogenicity of Takeda's TDV in Healthy Children

The purpose of this study is to assess the cellular immune responses following 2 doses of tetravalent dengue vaccine candidate (TDV) in 4 to 16 years' healthy participants.


Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

This trial will evaluate the use of a tetravalent vaccine against dengue. Primary Objectives: - To describe the immune response to dengue before and after each vaccination with dengue vaccine in two age cohorts of children previously vaccinated with yellow fever (YF) vaccine - To evaluate the safety of each vaccination with dengue vaccine in two age cohorts of children.

Efficacy and Safety of Dengue Vaccine in Healthy Children

There is currently no vaccine against dengue and no specific drug treatment against the disease. This study is aimed at generating information on the protective effect of the vaccine. Primary Objective To assess the efficacy of dengue vaccine after three injections in children. Secondary Objective: To evaluate the reactogenicity of dengue vaccine after each injection in a subgroup of children.

A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children

To assess the safety, reactogenicity and immunogenicity of two doses of the dengue vaccine

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

This trial will evaluate the use of a tetravalent vaccine against dengue. Primary objectives: - To describe the immune response to dengue before and after each vaccination with tetravalent dengue vaccine in adults, adolescents, and children. - To evaluate the safety of each vaccination with sanofi pasteur's tetravalent dengue vaccine in 4 age cohorts. - To evaluate the persistence of antibodies against dengue during 5 years after the first ...

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

The aim of the study is to evaluate the safety and immunogenicity of the Dengue vaccine in a population of special interest, such as HIV-positive adults. Primary Objective: - To describe the safety of each injection of CYD dengue vaccine in HIV-positive adults. Secondary Objectives: - To describe the humoral immune response to each dengue serotype at baseline and after each injection of CYD dengue vaccine in HIV-positive adults. - To detect the CY...

Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2

Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priority. This study will evaluate the ability of a single dose of a trivalent dengue vaccine to protect against infection with an attenuated candidate DENV-2 vaccine, administered 6 months after the trivalent dengue vaccine.

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

This is part of an ongoing effort to develop a satisfactory dengue vaccine: Primary objective: To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates. To describe the immune response after each vaccination of dengue vaccine.

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Primary Objectives: - To evaluate safety after each CYD Dengue vaccination. - To evaluate the immune response to each CYD Dengue serotype after each vaccination in a subset of subjects.

Dengue Serostatus Study

This is an observational study which will last for 5 years, and aims to determine the risk of developing dengue among Philippine children who are eligible to receive the dengue vaccine during the DOH mass dengue vaccination, by dengue serostatus at baseline.

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Primary objectives: - To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine. - To evaluate the safety of each vaccination with sanofi pasteur's CYD dengue vaccine.

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

The aim of the study is to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule. Primary Objective - To demonstrate the non-inferiority, in terms of geometric mean of titer ratios (GMTRs), of a CYD dengue vaccine booster compared to the third CYD dengue vaccine injection in subjects from previous CYD dengue vaccine trials. Secondary Objectives: - If the primary obje...

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

The purpose of this study is to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.

A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and children.

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60 years living in country(ies) non-endemic for both dengue and YF.

Safety Study of a Dengue Virus DNA Vaccine

The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

Dengue viruses can cause dengue fever and other more severe forms of disease. This study will evaluate the safety and immune response to two doses of a dengue virus vaccine given 12 months apart in healthy adults.

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will test whether a vaccine developed to prevent infection with dengue virus type 2 causes a response in people's immune system and is safe.

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

Dengue fever, caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a 2-dose regimen of a new monovalent dengue virus vaccine. This study will test the dengue virus vaccine DEN1delta30 in healthy adults.

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study. A prime-boost study of tetravalent dengue virus purified inactivated vaccine (TDENV-PIV) with the GSK AS03B adjuvant and tetravalent dengue live attenuated virus (TDENV-LAV) vaccine Formulation 17 (F17) will gather data to help better understand the human immune response to dengue vaccination and infection...

Follow-Up Study of Thai Children From Dengue-003 and Evaluation of a Booster Dose of Dengue Vaccine

The purpose of this study is to assess the immunogenicity of a booster dose of tetravalent live attenuated dengue vaccine administered approximately one year following the second dose.

Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine

Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

The aim of the study is to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a flavivirus with JE vaccine. Primary Objectives: - To describe and compare the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose. - To describe the persistence of the humoral immune response to each of the 4 parental dengue virus serotypes 6 months after CY...


More From BioPortfolio on "Takeda opens vaccine plant dengue shot shows promise"

Quick Search